Incyte's Zynyz Approved By European Commission As First-Line Treatment For Advanced SCAC With Platinum-Based Chemotherapy

Incyte's Zynyz (retifanlimab) has been approved by the European Commission as the first systemic treatment for adult patients with advanced squamous cell carcinoma of the anal canal (SCAC) in combination with platinum-based chemotherapy (carboplatin and paclitaxel). This approval is based on the POD1UM-303 study, which demonstrated significantly improved progression-free survival for patients receiving Zynyz compared to chemotherapy alone. The approval marks a significant advancement in treatment options for this patient population.